Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • +1 (905) 565-9495 Request Information
  • French
  • Part of brands: |
  • Part of brands: |
  • PATIENT JOURNEY
    • Before Pregnant
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • CGT
      • PGT-A Plus
      • PGT-A
      • PGT-SR
      • EMBRACE
      • PGT-M
      • NACE
      • POC Portfolio
      • SAT
      • Infertility Panels
  • Kit Request
  • Genetic Counselling
  • About us
    • Igenomix Research
    • About Igenomix
  • Academy
  • CFAS 2023
  • Webinars
Our Services > Oncodona

Oncodona

A complete test of genetic screening that analyzes 21 genes related to breast and ovarian cancer.

  • Overview
  • Features
  • How does it Work?
  • I’m a health specialist

Early identification of predisposition to inherited cancer.

Results in 30 days.

Harmful mutations can be transmitted with a 50% probability.

Overview

What is Oncodona test?

  • Oncodona is the most advanced genetic test for early identification of predisposition to inherited cancer.
  • This test analyzes 21 genes related to breast and ovarian cancer in order to locate mutations that increase the risk of developing these types of cancer.
  • Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.
Features
  • Indications
  • Benefits

Is Oncodona for you?

This test is recommended if:

  • You’ve been diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. Oncodona can find a mutation in up to 4% of women.
  • A woman in your family has been diagnosed with breast and ovarian cancer. 
  • You just want to know if you have any risk of developing breast and ovarian cancer.

Why use Oncodona?

  • The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
  • A negative result means that the patient does not have an increased risk. In other words, their risk of suffering one of the types of cancer analysed by the test is the baseline risk of the population.
How does it work?

BROCHURE

Download
email

Subscribe to
our newsletter

Other services you may be interested

CGT

Carrier Genetic Test
Determines the risk of having a child with a genetic disease

More information

PGT-M

Prevents the transmission of single gene disorders

More information

PGT-A

Improves the chances of reproductive success by selecting chromosomally normal embryos

More information

Igenomix is in the media

Igenomix is not affiliated with any news outlet or publication identified above. News coverage does not constitute an endorsement of Igenomix or its products.

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

OUR SERVICES

Genetic solutions
Learn about genetics

ABOUT US

About Igenomix
Contact
Quality
Work with us

FOLLOW IGENOMIX

*CAP accreditation applies to the LA lab.

  +1 (905) 565-9495  fax +1 (905) 671-1938
  Email us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Language

[2024] © Igenomix Privacy policy Quality policy Terms & conditions User Feedback

Request Information

  • PATIENT JOURNEY
    • Before Pregnant
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • CGT
      • PGT-A Plus
      • PGT-A
      • PGT-SR
      • EMBRACE
      • PGT-M
      • NACE
      • POC Portfolio
      • SAT
      • Infertility Panels
  • Kit Request
  • Genetic Counselling
  • About us
    • Igenomix Research
    • About Igenomix
  • Academy
  • CFAS 2023
  • Webinars
  • French
  • Canada